Skip to main content
FUTURA MEDICAL PLC logo

FUTURA MEDICAL PLC — Investor Relations & Filings

Ticker · FUM ISIN · GB0033278473 LEI · 21380053QLT46UNV2303 IL Manufacturing
Open in API
Filings indexed 571 across all filing types
Latest filing 2025-11-13 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL FUM

About FUTURA MEDICAL PLC

https://www.futuramedical.com/

Futura Medical is a pharmaceutical company specializing in the research, development, and global commercialization of innovative sexual health products. The company's core strength is its expertise in proprietary, topically delivered gel formulations. Its lead product, Eroxon®, is a clinically proven, fast-acting topical gel for the treatment of erectile dysfunction (ED). Eroxon® is distinguished by its rapid onset of action, helping users achieve an erection within 10 minutes, and is available over-the-counter in major markets including the USA and Europe. The company utilizes a de-risked commercialization strategy, establishing partnerships with leading consumer healthcare companies for distribution and marketing. Futura Medical's development pipeline also includes potential treatments for female sexual dysfunction.

Recent filings

Filing Released Lang Actions
Fundraise of £2.75 million
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement from Futura Medical PLC regarding a £2.75 million fundraise, board changes, and a notice of a General Meeting. It details the issuance of new shares, the purpose of the capital, and the necessity of shareholder approval for the conditional portions of the fundraise. While it mentions a circular will be issued, the document itself is the primary announcement of the capital raise and the associated corporate actions (fundraising, board changes, and meeting notice). Therefore, it is classified as a Capital/Financing Update.
2025-11-13 English
Total Voting Rights
Regulatory Filings Classification · 1% confidence The document is an official RNS (Regulatory News Service) announcement from Futura Medical plc regarding 'Total Voting Rights'. It specifies the total issued share capital and the number of voting rights to be used by shareholders for transparency rule calculations. This type of disclosure is a standard regulatory requirement for companies listed on the London Stock Exchange (AIM) and does not fit into specific categories like M&A, dividends, or financial reports. Therefore, it is classified as a general Regulatory Filing (RNS).
2025-11-03 English
Results for the six months ended 30 June 2025
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for Futura Medical plc covering the six-month period ended 30 June 2025. It includes detailed financial statements, operational reviews, management commentary, and a CEO review. It is clearly an interim financial report rather than an announcement of a report, as it contains substantive financial data and analysis. H1 2025
2025-09-30 English
Notice of Results and Investor Presentation
Report Publication Announcement Classification · 1% confidence The document is a short announcement (under 5,000 characters) from Futura Medical plc titled 'Notice of Results & Investor Presentation'. It informs shareholders that the company will release its interim results on a future date (30 September 2025) and provides details for an upcoming webinar. Per the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore qualifies as a Report Publication Announcement (RPA).
2025-09-26 English
Trading, Business and Strategic Review Update
Regulatory Filings Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from Futura Medical plc. It provides a 'Trading, Business and Strategic Review Update', specifically detailing that financial performance for the year will be below expectations due to slower sales and delayed milestone payments. It also discusses cash runway and restructuring plans. While it mentions an upcoming interim report, this document itself is an earnings-related update/announcement rather than the full report, and it does not fit the criteria for a full 10-K, IR, or other specific report types. It is a regulatory announcement regarding company performance and strategy.
2025-09-19 English
Total Voting Rights
Regulatory Filings Classification · 1% confidence The document is a standard regulatory announcement regarding 'Total Voting Rights' issued via the London Stock Exchange's RNS service. It provides the total number of issued shares and voting rights to assist shareholders with Disclosure and Transparency Rule requirements. This type of filing is a standard regulatory disclosure that does not fit into specific categories like M&A, dividends, or financial reports, making 'RNS' (Regulatory Filings) the most appropriate classification.
2025-08-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.